ASH 2024 Summary: Highlights in CML

2024 ASH Annual Meeting Insights Hub

J. Yang

ASH 2024 Review: Practice-Changing Updates in the Management of CML

Cleveland Clinic Taussig Cancer Institute

A. Jain

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

Year in Review 2024: CML Highlights

Oncology 2024 Year in Review

J. Cortés

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

Is Post-HSCT Maintenance the SOC for AML?

Rush University Medical Center

M. Levis

Experts Discuss How They Use Asciminib in Their CML Practice

MyCancerHaven

R. Vij, J. Zeidner

Efficacy and Safety of Asciminib in Ph+ CML

Luke Fletcher

Current Treatment Landscape in Myeloid Malignancies

Houston Methodist

S. Shah

Highlights of ASH 2024: Key CML Oral Presentations

International CML Foundation

T. Hughes

Leukemia Tumor Board: Navigating Ambiguous Leukemia - CML-BP/MPAL

Tisch Cancer Institute at Mount Sinai

J. Anderson

Updates on Myeloproliferative Neoplasms Including CML

Winship Cancer Institute - Emory University

A. Hunter

Treating Fibrosis and Inflammation in GvHD

Pooja Khandelwal

Highlights of ASH 2024: CML Biology Overview

International CML Foundation

S. Branford

Controversies in the Management of CML in 2024

Indy Hematology Review

R. Larson

Highlights of Recent Updates in CML: Impact on Practice

2024 ASCO® Annual Meeting Insights Hub

E. Atallah

Clinical Highlights in CML From EHA

International CML Foundation

A. Hochhaus

Chronic GVHD: Review Advances in Prevention, Novel Endpoints, and Ta…

City of Hope

I. Amanam

SOHO 2023: The New ELN Laboratory Recommendations for the Diagnosis …

SOHO 2023 Eleventh Annual Meeting

N. Cross